157 related articles for article (PubMed ID: 32200460)
1. Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma.
Scartoni D; Amelio D; Palumbo P; Giacomelli I; Amichetti M
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1615-1622. PubMed ID: 32200460
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Minniti G; Scaringi C; Baldoni A; Lanzetta G; De Sanctis V; Esposito V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):285-91. PubMed ID: 23642624
[TBL] [Abstract][Full Text] [Related]
3. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Pollom EL; Fujimoto D; Wynne J; Seiger K; Modlin LA; Jacobs LR; Azoulay M; von Eyben R; Tupper L; Gibbs IC; Hancock SL; Li G; Chang SD; Adler JR; Harsh GR; Harraher C; Nagpal S; Thomas RP; Recht LD; Choi CYH; Soltys SG
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):123-130. PubMed ID: 28586949
[TBL] [Abstract][Full Text] [Related]
4. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL.
Caissie A; Nguyen J; Chen E; Zhang L; Sahgal A; Clemons M; Kerba M; Arnalot PF; Danjoux C; Tsao M; Barnes E; Holden L; Danielson B; Chow E
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1238-45. PubMed ID: 22172909
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Osoba D; Brada M; Yung WK; Prados M
J Clin Oncol; 2000 Apr; 18(7):1481-91. PubMed ID: 10735896
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of health-related quality of life in Lithuanian brain tumor patients using the EORTC brain cancer module.
Bunevičius A; Tamašauskas Š; Tamašauskas A; Deltuva V
Medicina (Kaunas); 2012; 48(11):588-94. PubMed ID: 23455894
[TBL] [Abstract][Full Text] [Related]
8. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
Clement PMJ; Dirven L; Eoli M; Sepulveda-Sanchez JM; Walenkamp AME; Frenel JS; Franceschi E; Weller M; Chinot O; De Vos FYFL; Whenham N; Sanghera P; Looman J; Kundu MG; Peter de Geus J; Nuyens S; Spruyt M; Gorlia T; Coens C; Golfinopoulos V; Reijneveld JC; van den Bent MJ
Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
Taphoorn MJ; Stupp R; Coens C; Osoba D; Kortmann R; van den Bent MJ; Mason W; Mirimanoff RO; Baumert BG; Eisenhauer E; Forsyth P; Bottomley A; ; ;
Lancet Oncol; 2005 Dec; 6(12):937-44. PubMed ID: 16321761
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
12. Prospective Longitudinal Assessment of Quality of Life and Activities of Daily Living as Patient-Reported Outcome Measures in Recurrent/Progressive Glioma Treated with High-dose Salvage Re-irradiation.
Maitre P; Gupta T; Maitre M; Goda J; Krishnatry R; Chatterjee A; Sridhar E; Sahay A; Mokal S; Moiyadi A; Shetty P; Patil V; Jalali R
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e155-e165. PubMed ID: 32917486
[TBL] [Abstract][Full Text] [Related]
13. Impact of Radiation Target Volume on Health-Related Quality of Life in Patients With Low-Grade Glioma in the 2-Year Period Post Treatment: A Secondary Analysis of the EORTC 22033-26033.
Dirven L; Reijneveld JC; Taphoorn MJB; Coens C; El-Badawy SA; Tzuk-Shina T; Bravo-Marques J; Back M; Stalpers LJA; Stupp R; Baumert BG; Seidel C
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):90-100. PubMed ID: 30716525
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life and neurocognitive functioning in patients with recurrent glioblastoma treated with intracerebral immune checkpoint inhibition.
Geens W; Vanlaer N; Nijland L; Van Laere S; Schwarze JK; Bruneau M; Neyns B; Rogiers A; Duerinck J
J Neurooncol; 2024 May; 168(1):159-169. PubMed ID: 38502281
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients.
Wick W; Krendyukov A; Junge K; Höger T; Fricke H
J Neurooncol; 2019 Dec; 145(3):531-540. PubMed ID: 31679112
[TBL] [Abstract][Full Text] [Related]
16. Effect of disease burden on health-related quality of life in patients with malignant gliomas.
Osoba D; Brada M; Prados MD; Yung WK
Neuro Oncol; 2000 Oct; 2(4):221-8. PubMed ID: 11265231
[TBL] [Abstract][Full Text] [Related]
17. Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.
Maringwa J; Quinten C; King M; Ringash J; Osoba D; Coens C; Martinelli F; Reeve BB; Gotay C; Greimel E; Flechtner H; Cleeland CS; Schmucker-Von Koch J; Weis J; Van Den Bent MJ; Stupp R; Taphoorn MJ; Bottomley A;
Ann Oncol; 2011 Sep; 22(9):2107-2112. PubMed ID: 21324954
[TBL] [Abstract][Full Text] [Related]
18. The assessment of health-related quality of life and related factors in Chinese elderly patients undergoing chemotherapy for advanced cancer: a cross-sectional study.
Li Q; Lin Y; Qiu Y; Gao B; Xu Y
Eur J Oncol Nurs; 2014 Aug; 18(4):425-35. PubMed ID: 24721179
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
Kemmler G; Holzner B; Kopp M; Dünser M; Margreiter R; Greil R; Sperner-Unterweger B
J Clin Oncol; 1999 Sep; 17(9):2932-40. PubMed ID: 10561373
[TBL] [Abstract][Full Text] [Related]
20. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients.
Taphoorn MJ; Claassens L; Aaronson NK; Coens C; Mauer M; Osoba D; Stupp R; Mirimanoff RO; van den Bent MJ; Bottomley A;
Eur J Cancer; 2010 Apr; 46(6):1033-40. PubMed ID: 20181476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
